RIA Advisory Group LLC Buys 35,841 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

RIA Advisory Group LLC lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4,531.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 36,632 shares of the company’s stock after buying an additional 35,841 shares during the period. IDEXX Laboratories accounts for approximately 5.9% of RIA Advisory Group LLC’s holdings, making the stock its 5th largest holding. RIA Advisory Group LLC’s holdings in IDEXX Laboratories were worth $20,333,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. OFI Invest Asset Management acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at about $25,000. Valley National Advisers Inc. grew its holdings in IDEXX Laboratories by 84.6% during the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after purchasing an additional 22 shares during the period. Altshuler Shaham Ltd bought a new position in IDEXX Laboratories during the fourth quarter worth about $26,000. Geo Capital Gestora de Recursos Ltd bought a new position in IDEXX Laboratories during the third quarter worth about $28,000. Finally, Covestor Ltd grew its holdings in IDEXX Laboratories by 71.8% during the third quarter. Covestor Ltd now owns 67 shares of the company’s stock worth $29,000 after purchasing an additional 28 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 0.3 %

NASDAQ IDXX traded down $1.44 on Friday, reaching $476.35. The company had a trading volume of 565,634 shares, compared to its average volume of 429,183. The firm has a market cap of $39.56 billion, a price-to-earnings ratio of 47.45, a P/E/G ratio of 3.68 and a beta of 1.26. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The business has a 50 day moving average of $539.94 and a two-hundred day moving average of $508.49. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.17.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The business had revenue of $901.60 million during the quarter, compared to the consensus estimate of $891.88 million. During the same period in the prior year, the business posted $2.05 earnings per share. IDEXX Laboratories’s quarterly revenue was up 8.8% on a year-over-year basis. Analysts forecast that IDEXX Laboratories, Inc. will post 11.15 EPS for the current year.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of research analyst reports. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target for the company. in a report on Tuesday, January 30th. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. JPMorgan Chase & Co. boosted their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Barclays boosted their price objective on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Finally, The Goldman Sachs Group boosted their price target on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $591.50.

Insiders Place Their Bets

In other IDEXX Laboratories news, CFO Brian P. Mckeon sold 23,326 shares of the stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the completion of the sale, the chief financial officer now directly owns 29,718 shares in the company, valued at approximately $16,939,557.18. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, SVP George Fennell sold 8,198 shares of the firm’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the sale, the senior vice president now directly owns 6,712 shares in the company, valued at approximately $3,851,815.44. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Brian P. Mckeon sold 23,326 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the completion of the sale, the chief financial officer now owns 29,718 shares of the company’s stock, valued at $16,939,557.18. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,524 shares of company stock worth $24,871,960. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.